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Effect of octreotide, captopril or insulin on renal changes and UAE in
long-term experimental diabetes. Renal and glomerular growth is inher-
ent in early human and experimental diabetes frequently followed by later
increase in urinary albumin excretion (UAE). Treatment with angiotensin
converting enzyme (ACE) inhibitors has proven effective in delaying
progression of human and experimental diabetic renal changes, and so has
somatostatin analog treatment in experimental diabetes. The aim of the
present study was to investigate three weeks of octreotide and captopril
treatment alone or in combination following three months of untreated
experimental diabetes, and compare the effects to those of insulin
treatment. Diabetes induced significant increases in renal and glomerular
growth and urinary albumin excretion. Octreotide and captopril alone and
in combination reduced renal but not glomerular size, and the combined
administration reduced UAE. None of these schedules affected blood
glucose levels. Insulin treatment inducing euglycemia significantly reduced
renal and glomerular size and UAE. In conclusion, insulin treatment with
normalization of the diabetic metabolic derangement nearly normalizes
renal and glomerular growth and UAE after three months of untreated
diabetes. The combined treatment of octreotide and captopril was also
followed by a significant decrease in renal growth and reduction in UAE
compared to placebo treatment without affecting the metabolic control of
the diabetic animals.
Diabetic kidney disease develops in approximately 25 to 30% of
insulin-dependent diabetes mellitus (IDDM) patients and ac-
counts for a large number of patients who develop end-stage
kidney disease in Western countries. In the search for specific
pathogenetic factors and potential new treatments, interest has
focused on the effect of strict metabolic control and of blood
pressure lowering agents. However, several studies have also
suggested a role for growth factors in the development of diabetic
complications. Further, somatostatin analogs and angiotensin
converting enzyme (ACE) inhibitors have proven effective in
delaying development and progression of diabetic renal changes
in experimental diabetes [reviewed in 1–5].
The effect of ACE inhibitors is probably due to significant
reductions in blood pressure systemically as well as intraglomeru-
larly [reviewed in 3–5]. In addition, it has been demonstrated that
angiotensin II may be involved in the modulation of cell growth
and cell proliferation, and also involved in the synthesis of matrix
proteins under certain in vitro conditions [6, 7]. From these points
of view, studies of the modulation of the renin-angiotensin system
with ACE inhibitors in human and experimental diabetes seem
warranted.
In experimental diabetes, growth hormone (GH), insulin-like
growth factor I (IGF-I), as well as its binding proteins (IGFBPs)
have been suggested to play a role in early diabetic renal and
glomerular growth [reviewed in 1, 8–10]. In addition, GH and
IGF-I may be involved in the development of long-term experi-
mental diabetic renal damage with an increase in urinary albumin
excretion [11, 12]. Somatostatin analogs, which are potent inhib-
itors of GH and IGF-I, have been shown to inhibit the early
transient kidney IGF-I increase and renal hypertrophy following
diabetes induction in rats [13]. Further, somatostatin analog
administration for six months initiated from the day of diabetes
induction was followed by significantly lesser renal growth and
also a drastically reduced increase in urinary albumin excretion
(UAE) along with a reduction in serum and total kidney IGF-I
levels [11]. However, when octreotide treatment for three weeks
was postponed to after three or six months of untreated diabetes,
only a partial decrease in renal growth and no effect on UAE were
observed, and there was no effect on circulating or kidney IGF-I
levels [2]. In a recent study the early transient kidney IGF-I
increase following diabetes induction was restricted to the renal
cortex, while no significant changes in renal medulla IGF-I levels
were seen [14]; however, data on local IGF-I changes in long-term
experimental diabetes have not yet been published.
Experimental diabetes studies on intervention with octreotide
(a somatostatin analog) and ACE inhibitors initiated after a
considerable diabetes duration are still sparse, though they may
provide relevant clinical information. Further, the combined
administration of a somatostatin analog and an ACE inhibitor has
not been investigated, though the use of drugs with different
points of attack may prove advantageous. The aim of the present
study was to examine the effect of octreotide and captopril
administration either alone or in combination, and to compare the
treatment to that of insulin treatment for three weeks following an
untreated diabetes period of three months. Objective parameters
in the present study were renal and glomerular growth, UAE,
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blood pressure, and serum and local renal cortex and medulla
IGF-I levels.
METHODS
Animals
Adult female Wistar rats (Møllegaards Avlslab., Eiby, Den-
mark) with a mean body wt of 192 6 5 grams (SEM) at the start of
the experiment were studied. Rats were housed two to three per
cage in a room with a 12:12 hour (06.30 to 18.30 hr) artificial light
cycle, temperature of 21 6 2°C, and humidity of 55 6 2%. The
animals had free access to standard rat chow (Altromin, Lage,
Germany) and tap water throughout the experiment. The animals
were randomized into six groups matched for body wt: (1)
non-diabetic control rats (N 5 24); (2) diabetic rats, placebo
treated (N 5 18); (3) diabetic rats, octreotide treated (N 5 12);
(4) diabetic rats, captopril treated (N 5 12); (5) diabetic rats,
octreotide and captopril treated (N 5 12); (6) diabetic rats,
insulin-treated (N 5 10). Diabetes was induced on day 0 by i.v.
injection of streptozotocin (STZ; 50 mg/kg body wt) in acidic
0.154 mol/liter NaCl (pH 4.5) following 12 hours of food depri-
vation. Twenty-four hours after the administration of STZ the
animals were weighed, urinalysis was performed for glucose, and
ketones and tail-blood glucose determined. The body wt, urine
and tail blood analyses as well as food intake were measured once
a month for the first three months and twice a week during the
three weeks of intervention. Octreotide was dissolved in acetic
acid buffer 50 mmol/liter, pH 4.9 (500 mg/ml), and animals in
groups 3 and 5 were injected subcutaneously twice daily for three
weeks with 0.2 ml equivalent to 200 mg octreotide per day
following three months of untreated diabetes. Captopril was
dissolved in 0.9% saline at a concentration of 6.0 mg/ml, and rats
in groups 4 and 5 were injected subcutaneously twice daily during
the three-week treatment period with a dose of 30 mg/kg body
wt/day. Placebo-treated diabetic rats were injected subcutaneously
twice daily with 0.2 ml of acetic acid buffer 50 mmol/liter, pH 4.9,
during the three-week intervention period. Insulin treatment with
a heat-treated, very long-acting bovine ultralente insulin (Novo
Nordisk A/S, Bagsværd, Denmark) was started in group 6 after
three months of untreated diabetes. Insulin was given in an initial
dose of 6 IU followed by 2 to 4 IU depending on morning blood
glucose values.
By the end of the three-week intervention period following
three months of untreated diabetes, six animals from each exper-
imental group were randomly selected and systolic blood pressure
measured using the tail cuff technique [15]. Blood pressure values
represent the mean of four to five determinations in each of the
six rats from each group.
Non-diabetic control rats (group 1) were investigated on day 0,
after three months, and at the end of the study period after three
months 1 three weeks (8 rats each day). Diabetic placebo-treated
rats (group 2) were examined after three months and at the end of
the study period after three months 1 three weeks (8 and 10 rats,
respectively). At the end of the three-week treatment periods
after three months of untreated diabetes, diabetic rats in groups 3,
4, 5, and 6 were investigated (10 to 12 rats from each group as
described above).
At the end of the study period the animals were anesthetized
with sodium barbital (50 mg/kg body wt i.p.), blood drawn from
the retro-orbital venous plexus, and rats rapidly dissected to
obtain the kidneys. The right kidneys were weighed, cut into 2 mm
thick slices by a set of spaced razor blades and macroscopically
separated into renal cortex and medulla, and immediately frozen
in liquid nitrogen and stored at 280°C until further analysis. The
left kidneys were gently stripped of their capsules, weighed, and
fixed in 3% formaldehyde and 1% glutaraldehyde in modified
Tyrode buffer overnight. The fixed kidneys were then cut into 2
mm thick slices by a set of spaced razor blades and embedded in
paraffin. Sections were prepared from the “right-hand cut side” of
each slice at two different levels with a distance of 250 mm. This
provided a set of randomly positioned spaced sections in the
kidney. Sections 5 mm thick were stained with Periodic acid-Schiff
(PAS) and used for standard stereological measurements [16, 17]
(see below).
Determination of metabolic parameters
Blood glucose and urinalysis. Blood glucose was measured in
tail-vein blood by Haemoglucotest 1-44 and Reflolux II reflec-
tance meter (Boehringer-Mannheim, Mannheim, Germany).
Urine glucose and ketones were determined by Neostix 4 (Ames
Limited, Stoke Poges, Slough, UK).
Kidney and serum IGF-I measurements
IGF-I extractions from kidney and serum, and IGF-I radioimmu-
noassay. Kidney IGF-I extraction was performed according to
D’Ercole, Stiles and Underwood [18], and serum IGF-I was
extracted using an acid-ethanol extraction. IGF-I radioimmuno-
assay was performed as previously described [2, 19].
Kidney morphology
Glomerular volume fraction (Vv, glomeruli/kidney) and total
glomerular volume (TGV) per kidney were estimated in non-
diabetic control animals examined at day 0 and at the end of the
study period. Diabetic placebo, octreotide, captopril, octreotide
and captopril, and insulin treated rats were examined at the end
of the three-week treatment period following three months of
untreated diabetes.
Point counting was performed in visual fields obtained by a
systematic independent sampling from the total area of PAS-
stained sections by the way of a DC-motor that secured a position
of glomerular profiles independent of the position of the grid. The
visual fields were projected at final magnification of 3385 onto a
grid with double set of points (coarse-to-fine points ratio 1:18). In
each animal an average of at least 100 fields of fine points hitting
glomeruli, P (Glomeruli), were analyzed; P (Glomeruli) was
defined as the glomerular tuft including space and capsule of
Bowman. In addition, fine points hitting any kidney tissue, P
(Kidney), were counted.
The glomerular volume fraction (Vv) is:
Vv ~glomeruli/kidney! 5 SP~Glom!/@36 3 SP~kidney!#
where SP(Glom) is the total number of points hitting glomeruli
and SP(kidney) is the total number of points hitting any kidney
tissue.
The total glomerular volume (TGV) in the kidney is then
TGV 5 Vv~glomeruli/kidney! 3 kidney wt ~g!
expressed as cubic millimeter per kidney, assuming that 1 g kidney
tissue equals 1,000 mm3.
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Urinary albumin excretion (UAE). Each rat from each of the
experimental groups was placed in metabolic cages in order to
collect 24-hour urine specimens by day 0 (group 1), after three
months (group 1 and 2), and by the end of the study period
(groups 1 to 6). The urinary albumin concentration in 24-hour
urine collections was determined by radioimmunoassay as previ-
ously described [20] using rat albumin antibody and standards.
The urine samples were stored at 280°C until the assay was
performed. Rabbit anti-rat albumin antibody RARa/Alb was
purchased from Nordic Pharmaceuticals and Diagnostics (Til-
burg, The Netherlands). For standard and iodination a globulin-
free rat albumin was obtained from Sigma Chemical Co. (St.
Louis, MO, USA).
Statistical analysis
All results are given as mean values 6 SEM. Differences between
groups were analyzed by one-way analysis of variance (ANOVA)
in combination with the Duncan principle for multiple compari-
sons for data following a normal distribution. The UAE data
followed a normal distribution after logarithmic transformation
and group means of transformed data were tested by one-way
analysis of variance (ANOVA) in combination with the Duncan
principle for multiple comparisons. Statistics were performed by
the statistical package SOLO, BMDP Statistical Software (Los
Angeles, CA, USA). P , 0.05 was considered statistically signif-
icant in a two-tailed test.
RESULTS
Body weight
Diabetes induction was followed by an initial small decrease in
body wt and then by a significantly slower increase compared to
non-diabetic control rats during the study period (Fig. 1). There
was no effect of the three week treatment with octreotide,
captopril or the combined treatment of octreotide and captopril
on body wt changes when compared to placebo-treated diabetic
rats. However, insulin treatment of diabetic rats was followed by
a significant increase in body wt compared to the placebo-treated
diabetic rats (P , 0.05), though a complete normalization was not
attained when compared to non-diabetic control rats (P , 0.05).
Blood glucose
Twenty-four hours after diabetes induction all diabetic animals
had blood glucose levels above 20 mmol/liter, which remained at
that level for the rest of the study period (Fig. 2). There was no
effect on blood glucose during the three week treatment with
octreotide, captopril, or octreotide and captopril in combination
when compared to placebo-treated diabetic rats. Insulin treat-
ment for three weeks was followed by a normalization of blood
glucose levels.
Food intake
Non-diabetic control animals had a food intake of 15 to 20 g/24
hr during the study period (Fig. 3). The diabetic animals were
characterized by hyperphagia from day 7 consumed 40 to 60%
more food than non-diabetic controls (P , 0.05). There was no
effect of octreotide, captopril, octreotide and captopril in combi-
nation on food intake when compared to placebo-treated diabetic
rats. Insulin-treated diabetic rats showed a normalization of food
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Fig. 1. Body weight changes during the study period in non-diabetic
control rats (F), placebo-treated diabetic rats (), octreotide-treated
diabetic rats (), captopril-treated diabetic rats (M), octreotide- and
captopril-treated diabetic rats (f), and insulin-treated diabetic rats ().
(a) P , 0.05, non-diabetic control rats compared to all other diabetic
groups during the study period. (b) P , 0.05, insulin-treated diabetic rats
compared to non-diabetic control rats and all other diabetic rats by the
end of the study period.
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Fig. 2. Blood glucose levels in non-diabetic control rats (F), placebo-
treated diabetic rats (), octreotide-treated diabetic rats (), captopril-
treated diabetic rats (M), octreotide- and captopril-treated diabetic rats
(f), and insulin-treated diabetic rats () during the study period.
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intake similar to non-diabetic control rats by the end of the
intervention period (P , 0.05).
Kidney weight
During the study period total kidney weight increased signifi-
cantly in non-diabetic control rats (P , 0.05; Fig. 4). Placebo-
treated diabetic rats showed a significantly greater increase in
kidney wt during the study period when compared to non-diabetic
control rats (P , 0.001). At the end of the three-week treatment
period following three months of untreated diabetes, octreotide
treatment and the combined treatment of octreotide and captopril
was followed by significantly lower kidney wt compared to place-
bo-treated diabetic rats (P , 0.05). Captopril treatment alone
resulted in only marginally lower total kidney wt compared to
placebo-treated diabetic rats (0.05 , P , 0.1); however, this slight
reduction was not different from octreotide or octreotide and
captopril-treated diabetic rats. Octreotide, captopril, and oct-
reotide and captopril-treated diabetic rats still had significantly
higher total kidney weights compared to non-diabetic control rats
(P , 0.01). In contrast, insulin treatment for three weeks follow-
ing three months of untreated diabetes resulted in a near-
normalization of total kidney wt compared to non-diabetic control
rats (0.05 , P , 0.10) and significantly lower than all other
diabetic groups (P , 0.01).
Glomerular volume fraction and total glomerular volume
No significant changes in glomerular volume fraction (Vv) were
observed in any of the experimental groups during the study
period (Table 1). A significant increase in total glomerular volume
(TGV) in placebo-treated diabetic rats was found compared to
non-diabetic control rats (P , 0.01). No effect of octreotide,
captopril, or octreotide and captopril in combination was ob-
served on TGV compared to placebo-treated diabetic rats. How-
ever, insulin treatment for three weeks after three months of
untreated diabetes was followed by a significant decrease in TGV
compared to placebo and captopril-treated diabetic rats (P ,
0.01) with a TGV similar to that observed in non-diabetic control
rats (NS).
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Fig. 3. Food intake during the study period in non-diabetic control rats
(F), placebo-treated diabetic rats (), octreotide-treated diabetic rats
(), captopril-treated diabetic rats (M), octreotide- and captopril-treated
diabetic rats (f), and insulin-treated diabetic rats (). (a) P , 0.05
Non-diabetic control rats compared to all other diabetic groups during the
study period except insulin-treated diabetic rats by the end of the study
period.
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Fig. 4. Total kidney weight changes examined in non-diabetic control
rats (C) by day 0, non-diabetic controls and placebo-treated diabetic rats
(DP) after three months (day 3 m) and in non-diabetic control rats, and
in placebo-, octreotide- (DO), captopril- (DC), octreotide- and captopril-
(DCO), and insulin-treated diabetic rats (DI) by the end of the study
period (day 3m 13w). (a) P , 0.05 C rats by day 0 compared to C rats by
the end of study period. (b) P , 0.001 DP rats compared to C rats. (c) P ,
0.05 DO and DOC compared to DP rats by the end of the study period.
(d) DI rats compared to DP rats by the end of the study period.
Table 1. Glomerular volume fraction (glomeruli/kidney, Vv/%) and
total glomerular volume (TGV, mm3/kidney) examined by day 0 and at
the end of the study period
Day 0
Day 3 months 1 3
weeks
Vv TGV Vv TGV
Non-diabetic
controls
3.2 6 0.2 21.5 6 1.6 3.4 6 0.1 25.2 6 0.8
Diabetes placebo 3.0 6 0.1 31.6 6 1.6a
Diabetes octreotide 3.1 6 0.1 29.1 6 1.3
Diabetes captopril 3.2 6 0.1 30.9 6 1.3
Diabetes octreotide
and captopril
3.1 6 0.1 28.5 6 0.8
Diabetes insulin 3.3 6 0.1 26.1 6 0.9b
Values are mean 6 SEM.
a P , 0.01 compared to the non-diabetic rats
b P , 0.01 compared to to placebo- and captopril-treated diabetic rats
at the end of the study period
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Urinary albumin excretion
Diabetes induced a significant increase in urinary albumin
excretion (UAE) during the study period when compared to
non-diabetic control rats (P , 0.001; Fig. 5). By the end of the
study period the combined treatment of octreotide and captopril
was followed by a significant decrease in UAE when compared to
placebo-treated diabetic rats (P , 0.05), which was significantly
above that of the non-diabetic control rats (P , 0.01). Treatment
with octreotide or captopril alone resulted in only non-significant
reductions in UAE when compared to the placebo-treated dia-
betic rats. However, insulin treatment for three weeks after an
untreated diabetes period of three months was followed by a
normalization of UAE when compared to non-diabetic controls
(NS) and was significantly reduced compared to placebo-treated
diabetic rats (P , 0.01) and the octreotide and captopril treated
groups (P , 0.05).
Systolic blood pressure
By the end of the study systolic blood pressure was measured to
114 6 2 mm Hg in non-diabetic control rats compared to 124 6
6 mm Hg in the placebo-treated diabetic rats (NS). Insulin treated
(97 6 5 mm Hg), captopril treated (94 6 4 mm Hg) and
octreotide and captopril treated rats (92 6 5 mm Hg) had
significantly lower blood pressure measurements when compared
to non-diabetic controls and placebo-treated diabetic rats (P ,
0.05). Octreotide-treated diabetic rats had a blood pressure of
100 6 6 mm Hg, which was marginally lower than the placebo-
treated diabetic animals (0.05 , P , 0.1) and not significantly
different from non-diabetic control rats.
Serum IGF-I
An age dependent decrease in serum IGF-I was observed in
non-diabetic control rats (803 6 94 mg/liter by day 0 compared to
558 6 15 mg/liter after three months and 591 6 57 mg/liter by the
end of the study; P , 0.05). Diabetes induction was followed by a
further decrease in serum IGF-I after three months (447 6 8
mg/liter). By the end of the study period all diabetic animals had
significantly lower serum IGF-I levels compared to the non-
diabetic control rats (P , 0.001) except insulin-treated diabetic
rats, which had achieved a normalization of IGF-I levels (508 6 28
mg/liter; NS compared to non-diabetic controls). No significant
differences were observed between placebo-treated diabetic rats
(287 6 29 mg/liter) and the octreotide treated (347 6 28 mg/liter),
captopril treated (356 6 25 mg/liter), or octreotide and captopril
diabetic rats (330 6 35 mg/liter).
Renal cortex and medulla IGF-I
No change in renal cortex or medulla IGF-I levels was observed
in the non-diabetic control groups (Fig. 6). Throughout the study
period renal cortex contained significantly more (300 to 500%)
IGF-I compared to renal medulla in all experimental groups (P ,
0.01). All diabetic groups had significantly lower cortex IGF-I
contents compared to non-diabetic control rats after three months
and at the end of the study period (P , 0.05). Further, no effect
of octreotide, captopril, or the combined treatment of octreotide
and captopril was observed when compared to placebo-treated
diabetic rats (NS). However, insulin treatment was followed by a
normalization of cortex IGF-I levels compared to non-diabetic
control rats (NS) that was significantly above levels in the
placebo-treated diabetic rats (P , 0.05). In renal medulla from
non-diabetic control rats significantly more IGF-I was observed
compared to placebo, octreotide, octreotide and captopril, and
insulin-treated diabetic rats after three months and by the end of
the study period (P , 0.05).
DISCUSSION
In the present study diabetes induction was followed by signif-
icant increases in renal and glomerular growth and UAE, as
demonstrated after three months of untreated diabetes. The three
week intervention with octreotide or captopril resulted in a
reduction in kidney weight only, while the combined treatment in
addition to lower kidney weight also induced a significant reduc-
tion in UAE. These effects were seen without any influence on the
metabolic control. Insulin treatment was followed by a near-
normalization of kidney weight, TGV, and UAE along with
normalization of the diabetic metabolic derangement.
During the past years ACE inhibitors have proven effective in
delaying development and progression of diabetic kidney disease
along with significant reductions of blood pressure both systemi-
cally and intraglomerularly [4, 5]. In addition, ACE inhibitors may
prevent angiotensin II stimulated cell growth, proliferation, and
matrix protein synthesis, as demonstrated in certain in vitro
conditions [6, 21, 22]. In a recent study using high and low doses
of the ACE inhibitor trandolapril, no effect on early experimental
diabetic renal hypertrophy or IGF-I accumulation was observed
[23]. Zatz et al [24] demonstrated that diabetic renal growth was
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Fig. 5. Urinary albumin excretion (UAE) in non-diabetic control rats (C)
by day 0, non-diabetic controls and placebo-treated diabetic rats (DP)
after three months (day 3m) and in non-diabetic control rats, and
placebo-, octreotide- (DO), captopril- (DC), octreotide- and captopril-
(DOC), and insulin-treated diabetic rats (DI) by the end of the study
period (day 3m 13w). (a) P , 0.001, DP rats compared to C rats. (b) P ,
0.05, DOC rats compared DP rats and P , 0.01, compared to non-diabetic
control rats. (c) P , 0.01 DI rats compared to DP rats by the end of the
study period.
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significantly reduced after four to six weeks treatment with
enalapril but not after 14 months. Hajnazarian et al [25] have
recently demonstrated that long-term treatment with the ACE
inhibitor captopril from diabetes onset reduces renal enlargement
in experimental diabetes; however, normalization was not
achieved. This may suggest that ACE inhibitors have no effect on
the GH/IGF-I system in early and long-term experimental diabe-
tes. In the present study in which treatment was initiated after
three months of untreated diabetes we could not demonstrate any
effect of captopril on circulating or localized kidney IGF-I levels.
However, a tendency towards reduction in kidney weight was
observed.
The effect of somatostatin analogs in human and experimental
diabetes has been reviewed recently [1, 2], and it was demon-
strated that octreotide inhibits the early diabetic kidney IGF-I
accumulation and renal growth following diabetes induction.
When octreotide treatment was given for six months from the day
of diabetes induction, kidney weight and UAE were significantly
reduced compared to placebo-treated diabetic rats along with a
reduction in whole kidney and serum IGF-I levels [11]. In a
previous study three weeks of octreotide treatment was initiated
after three and six months of untreated diabetes, and we only
observed a trend towards a reduction in kidney weight, but there
was no effect on TGV [2]. Further, there was no effect of
octreotide on whole kidney or serum IGF-I levels compared to
placebo-treated diabetic rats when treatment was initiated at this
late time of diabetes [2]. Diabetes induction itself is followed by
significant reductions in circulating IGF-I levels, and if octreotide
treatment is initiated shortly or after a more prolonged diabetes
period, no further decrease in serum IGF-I levels can be achieved
by the octreotide treatment [2, 26]. This has also been demon-
strated in the present study, since no significant changes in serum
or localized kidney IGF-I levels were observed in octreotide-
treated diabetic rats compared to placebo treated rats. However,
somatostatin analog treatment may alter circulating and local
IGFBPs, and it has been demonstrated that the somatostatin
analog lanreotide significantly inhibited a 30 kDa serum band
(containing IGFBP-1) and the serum IGFBP-3 band in early
experimental diabetes using Western ligand blotting (unpublished
data). Octreotide treatment has recently been demonstrated to
inhibit increases in kidney IGFBP-1 mRNA expression in early
experimental diabetes [27]. In addition, somatostatin analogs
induce hemodynamic changes, as decreased renal plasma flow
(RPF) and glomerular filtration rate (GFR) have been reported in
human diabetes [28–30]. However, somatostatin was unable to
inhibit the IGF-I stimulated increase in GFR and RPF in normal
rats [31]. The effect of somatostatin analogs on renal hemody-
namics in experimental diabetes has not been examined yet.
In the present study the combined treatment of captopril and
octreotide resulted in significant reduction in UAE, while either
treatment alone had no significant effect. However, a significant
effect on total kidney weights was observed after treatment with
octreotide alone and in combination with captopril compared to
placebo-treated diabetic rats, but no additive effect of the com-
bined treatment on total kidney weights was observed. Captopril
treatment alone was followed by only a trend towards reduction in
kidney weight and no difference in kidney weights was observed
between any of these three groups by the end of the study.
Accordingly, the combined treatment with captopril and oct-
reotide, which theoretically has different target points in the
Fig. 6. IGF-I levels observed in renal cortex (A) and in renal medulla (B)
in non-diabetic control rats (C) by day 0, non-diabetic controls and
placebo treated diabetic rats (DP) after three months (day 3m) and in
non-diabetic control rats, placebo-, octreotide- (DO), captopril- (DC),
octreotide- and captopril- (DOC), and insulin-treated diabetic rats (DI)
by the end of the study period (day 3m 13w). (a) P , 0.05, non-diabetic
control rats compared to DP, DO, DC, and DOC rats after three months
and by the end of the study period. (b) DI rats compared to DP, DC, and
DOC rats by the end of the study period. (c) P , 0.05, non-diabetic control
rats compared to all other groups examined the same day.
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diabetic kidney, in general showed no further benefit compared to
either treatment alone. However, it is of interest that these renal
effects were seen without influence on the metabolic control of
the animals.
The effect of insulin treatment on diabetic renal changes has
been investigated thoroughly in previous studies. It was demon-
strated that insulin treatment inhibits the early diabetic kidney
IGF-I accumulation and renal growth following diabetes induc-
tion in rats [13]. In addition, insulin treatment inhibits glomerular
growth when treatment is initiated by the day of diabetes induc-
tion [32] and also reduces increase in basement membrane
thickening and UAE [32, 33]. In a previous study insulin treat-
ment was initiated for seven weeks after an untreated diabetes
period of 37 weeks followed by a normalization of kidney weight
and GFR [34]. Further, when insulin treatment for three weeks
was initiated after an untreated diabetes period of six months, a
significant decrease in kidney weight was observed compared to
placebo-treated diabetic rats, although normalization was not
achieved and no changes in TGV or UAE were observed [2]. In
the present study where insulin treatment was initiated for three
weeks after three months of untreated diabetes, a near-normal-
ization of kidney weight and a normalization of TGV and UAE
were demonstrated. This has been supported by Nyengaard,
Flyvbjerg and Rasch [35], who demonstrated a normalization of
kidney weight with strict insulin treatment for three weeks follow-
ing 10 weeks of untreated diabetes. There is a discrepancy in the
literature concerning the effect of diabetes duration on the
possibility of normalization of renal growth, and further, it is an
ongoing riddle how insulin treatment may “normalize” a hyper-
plasia with more than 30% increase in diabetic renal tubuli cell
number [35]. Part of the discrepancy may be explained by the
various preparations of the kidney before measuring its weight.
Stackhouse et al [34] and Nyengaard et al [35] measured perfusion
fixed kidney weights, while we have used renal wet weights [2].
Another artifact that may be involved in the apparant normaliza-
tion of kidney size may be the well described effects of hyperin-
sulinemia on water and protein transport in tissues [36, 37].
Logically, it is hardly possible that complete normalization may
take place following long-term untreated experimental diabetic
hyperplasia as well as hypertrophy. Altogether, we find support
for the view that a very early intervention with strict insulin
administration and normalization of diabetic metabolic abbera-
tion is important in order to completely reverse the renal changes
in experimental diabetes.
In early experimental diabetes a transient increase in whole
kidney IGF-I is a consistent finding followed by renal and
glomerular growth [13, 38, 39]. It has recently been demonstrated
that this early transient kidney IGF-I increase is most pronounced
in renal cortex while only modest changes are observed in renal
medulla, and further, that renal cortex IGF-I levels are signifi-
cantly above renal medulla IGF-I levels [14]. In line with this
observation, in the present long-term experimental diabetes study
kidney IGF-I levels were significantly higher in renal cortex
compared to renal medulla in both non-diabetic control rats and
diabetic rats. However, three months after diabetes induction a
decrease in cortex and medulla IGF-I levels was observed com-
pared to non-diabetic controls, and this reduced localized IGF-I
levels has previously been demonstrated in whole kidney homog-
enates [2, 11]. The regional differences in IGF-I levels observed in
early experimental diabetes were thus confirmed in the present
long-term diabetes study, that is, that the renal cortex contained
more IGF-I than renal medulla. Whether local IGF-I is involved
in the late development and progression of diabetic kidney disease
cannot be concluded from the present experiment. However,
regional studies of the kidney and different intervention regimens
may give more specific information on the GH/IGF-I axis in the
development and progression of diabetic kidney disease, as re-
viewed recently [10].
In conclusion, the combined treatment of octreotide and cap-
topril for three weeks following three months of experimental
diabetes reduced renal hypertrophy and UAE without changing
the metabolic control of the rats. The combined treatment was
more effective than treatment with either captopril or octreotide
alone concerning UAE, while similar effects on renal size were
seen on these regimens. In comparison, insulin treatment induc-
ing normalization of the diabetic metabolic deterioration was
followed by near-normalization of renal growth and normalization
of glomerular growth and UAE.
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